100-Year Human Aging Study
Current understanding
The 100-Year Human Aging Study is an announced prospective lifespan cohort designed to follow participants with comprehensive multi-system phenotyping (omic, clinical, functional) until death, with the explicit goal of validating which biomarkers — alone or in combination — predict all-cause and cause-specific mortality, incident serious disease, and functional disability. It targets the infrastructure gap that longevity medicine currently uses to justify surrogate-endpoint claims without hard-outcome anchoring. No results yet; the announcement itself is the artifact [expert-opinion].
Evidence log
- 2026-09-29 — Westlake Longevity Cohort: cross-connection with westlake-longevity-cohort: Both are newly announced prospective longevity cohorts banking multi-omic trajectories against mortality/healthspan outcomes; We-Longevity adds a Chinese centenarian/nonagenarian arm and explicit microbiota culturomics to the emerging century-scale cohort landscape. (novelty: 3)
- 2025-12-11 — Your brain doesn’t look a day past 70! Cross-sectional associations with brain-predicted age in the cognitively-intact oldest-old.: cross-connection with brain-mri-biological-age: Both address survivorship-selected extreme-age cohorts where conventional aging-biomarker associations attenuate or invert, underscoring the need for age-stratified reference models. (novelty: 3)
- 2026-09-09 — Longevity Metrics AI/ML Development Study: Longevity Metrics describes its video-scoring / imputation / life-expectancy AI pipeline as linked to the 100-Year Human Aging Study cohort as a data source — company development claim, no outcome readout or validation released. [expert-opinion] (novelty: 3)